secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001493152-24-049571
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections
----------------------------------------------------------------------------

- VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.
- Seed round term sheet (non-binding) for up to $3M in three tranches at valuations tied to Series A; 5,278 Class B shares issued.
- University of Miami (Bascom Palmer) receives minority equity; 5% ownership until $2M qualified investment.
- Initial directors: Webster Bailey, Jack Lacey, Ed Pershing (Chair). Officers: Dominic Rodrigues (Acting CEO), Heather Raines (Acting CFO).
- RB PDAT tested in >500 patients globally; targeting $60B ophthalmic market with broad-spectrum antimicrobial therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224049571/0001493152-24-049571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224049571/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-049571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer